Stockscreener 앱 받기
22.64
15.69%
3.07
시간 외 거래:
22.25
-0.39
-1.72%
Immunome Inc 주식(IMNM)의 최신 뉴스
Immunome Soars 15% as Phase 3 Trial of Desmoid Tumor Drug Achieves Overwhelming Success - NAI500
Cryptocurrencies, White House’s Tech Force, and Immunome: Stock Market News - thestreet.com
Why Immunome Stock Surged Today - Finviz
Immunome announces proposed public offering - MSN
IMNM: Key Managers Appointed for Upcoming Stock Offering - GuruFocus
Immunome plans to offer $400 million in common stock shares By Investing.com - Investing.com South Africa
The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying - Investor's Business Daily
Immunome Plans $400 Million Public Stock Offering - marketscreener.com
Immunome announces proposed public offering of common stock - marketscreener.com
Immunome (Nasdaq: IMNM) plans $400M share sale, 30-day $60M underwriter option - Stock Titan
Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug - Nasdaq
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more - CNBC
Immunome (NASDAQ:IMNM) Shares Gap UpStill a Buy? - MarketBeat
Immunome jumps after promising results for its desmoid tumor treatment - marketscreener.com
Ringside sends Immunome towards filing | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Immunome’s Varegacestat Shines in Phase 3 RINGSIDE Trial, Earning Buy Rating from Charles Zhu - TipRanks
Here’s Why Immunome Stock (IMNM) Soared Over 20% Today - TipRanks
Immunome’s desmoid tumor drug shows 84% reduction in disease progression - Investing.com Australia
Wedbush Adjusts Immunome Price Target to $31 From $21, Maintains Outperform Rating - marketscreener.com
Immunome Target of Unusually High Options Trading (NASDAQ:IMNM) - MarketBeat
Immunome's desmoid tumor treatment triumphs in phase 3, setting up approval filing - Fierce Biotech
Immunome’s rare tumor drug passes Phase 3 test, could challenge Merck KGaA - Endpoints News
Immunome reports RINGSIDE trial met primary, secondary endpoints - TipRanks
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025) - ts2.tech
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep - BioSpace
Why Is IMNM Stock Rising Today? - Stocktwits
Immunome posts Phase III success for desmoid tumour therapy - FirstWord Pharma
Immunome (IMNM) Reports Positive Phase 3 Results for Varegacesta - GuruFocus
Immunome shares jump on strong phase 3 data for desmoid tumor therapy - MSN
Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data - GuruFocus
Immunome stock surges after positive Phase 3 trial results By Investing.com - Investing.com Nigeria
Immunome rises after positive data from experimental tumor treatment - TradingView — Track All Markets
Immunome stock surges after positive Phase 3 trial results - Investing.com
Immunome Announces Positive Phase 3 Trial Results - TipRanks
Immunome announces positive topline results from phase 3 Ringside trial of Varegacestat in patients with desmoid tumors - marketscreener.com
Immunome's experimental drug meets main goal in late-stage study - marketscreener.com
Immunome Inc Announces Positive Phase 3 RINGSIDE Trial Results - TradingView — Track All Markets
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - BioSpace
What analysts say about Immunome Inc stockStock Buyback Announcements & Outstanding Growth Strategies - earlytimes.in
Immunome (IMNM) targets $400M equity raise to back varegacestat and oncology pipeline - Stock Titan
Immunome to disclose Phase 3 RINGSIDE trial results for desmoid tumors - Investing.com Nigeria
Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. $IMNM Stock Holdings Decreased by Redmile Group LLC - MarketBeat
Natixis Invests $2.13 Million in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Immunome (NASDAQ:IMNM) Reaches New 1-Year HighTime to Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Hits New 12-Month HighHere's Why - MarketBeat
Immunome stock hits 52-week high at $20.50 - Investing.com
Immunome stock hits 52-week high at $20.50 By Investing.com - Investing.com UK
Marshall Wace LLP Sells 312,956 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunome, Inc. (IMNM) -6.5% in After-hours: What’s Driving the Move? - Stocks Telegraph
Can Immunome Inc stock deliver strong Q4 earningsTrade Volume Report & Risk Managed Investment Signals - moha.gov.vn
What drives Immunome Inc stock priceEarnings Surprise Analysis & Make Confident Moves With Forecasting Models - earlytimes.in
Understanding Momentum Shifts in (IMNM) - news.stocktradersdaily.com
Is Immunome Inc (IMNM) positioned for future growth? - setenews.com
Kennedy Capital Management LLC Purchases 94,627 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome initiated with a Buy at Truist - MSN
Tema Etfs LLC Takes $1.07 Million Position in Immunome, Inc. $IMNM - MarketBeat
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome (NASDAQ:IMNM) Stock Price Up 9.5%Time to Buy? - MarketBeat
Is Immunome Inc a good long term investmentSwing Trading Ideas & Superior Capital Appreciation - earlytimes.in
0.36%
1.05%
자본화:
|
볼륨(24시간):